1 Introduction
==============

Gene expression is believed to have influenced human evolution and play a key role in diseases ([@btx509-B3]). Thus, it is critical for understanding diseases and developing treatments. The importance of gene expression was further underlined by the enrichment of association signals in SNPs tagging gene expression ([@btx509-B11]; [@btx509-B12]), which are denoted as expression quantitative trait loci (eQTL).

Currently, the identification of complex disease susceptibility loci is performed via genome-wide association studies (GWAS). It involves scanning single nucleotide polymorphisms (SNPs) across the entire genome for genetic variants associated with a trait. Univariate analysis of GWAS is still the de facto tool for identifying trait associated SNPs ([@btx509-B15]). However, when analyzing more complex GWAS SNPs with weak or moderate effect sizes, the significant findings account only for a small fraction of the total trait variation ([@btx509-B9]). Due to their small effect sizes, these SNPs are rarely detected in GWAS ([@btx509-B16]). To increase the power of detection, researchers proposed analyzing genetic variants multivariately ([@btx509-B14]).

One type of multivariate analyses is the transcriptome-wide association study (TWAS) which identifies significant expression-trait associations. Such methods, e.g. joint effect on phenotype of eQTL/functional SNPs associated with a gene (JEPEG) ([@btx509-B6]), PredictXcan ([@btx509-B4]), JEPEGMIX ([@btx509-B7]) and TWAS ([@btx509-B5]) use eQTL to predict gene expression and/or infer which genes are associated with traits. However, unlike competing non-eQTL paradigms, e.g. LDscore/LDpred ([@btx509-B1]), current TWAS methods (i) lack competitive adjustment for background enrichment ('average signal') and (ii) do not output *q*-values that control false positive rates when there is a substantial number of genes enriched (above background) in signals.

To address these shortcomings, we propose JEPEGMIX2, an extension of JEPEGMIX, which, in addition to the existing advantage of imputing eQTLs statistics and inferring gene-trait association in cosmopolitan cohorts, it also (i) adjusts for background enrichment, (ii) offers the option to upweight rarer eQTLs and (iii) to avoid false positive rate increase for high signal enrichment, it outputs Holm *q*-values.

2 Materials and methods
=======================

To avoid a mere accumulation of just averagely enriched polygenic information, we competitively adjust $\chi^{2}$ statistics for background enrichment. This is achieved by adjusting the statistic for average non-centrality. Such 'centralized' JEPEGMIX statistic we denote as competitive (C) and the original statistic as the non-competitive (NC).

Let $Z$ be the vector of $Z$-scores for measured SNPs in the genome scans. Due to polygenicity, the expected genome scan $\chi_{1}^{2} = Z^{2}$ statistics, each with 1 degree of freedom (df), has a non-zero background noncentrality parameter $\lambda^{2}$, i.e. $E\left( Z^{2} \right) = 1 + \lambda^{2}$. Thus, by the method of moments, we can estimate $\hat{\lambda^{2}} = \overset{-}{Z^{2}} - 1$, where $\overset{-}{Z^{2}}$ is computed using all measured SNPs in the genome scan, However, given that $\lambda^{2} \geq 0$, a better estimator is, thus, $\hat{\lambda^{2}} = max\left( \overset{-}{Z^{2}} - 1,~0 \right)$. To develop a competitive test, before computing gene-level statistics, Z-scores must be shrunk towards zero by adjusting for the average background enrichment. This can be achieved via a 3 step process: Recompute, under 'average' noncentrality, the *P*-value associated with $\chi_{1}^{2}~$statistics:$~P' = 1 - F\left( Z^{2} \right.$\|$~\hat{\lambda^{2}}$), where $F\left( . \right.$\|$~\hat{\lambda^{2}}$), is the cumulative distribution function (cdf) of the non-central $\chi_{1}^{2}$ distribution with 1 df and noncentrality parameter $\hat{\lambda^{2}}$.Transform $P'$ into its quantile vector from a central $\chi_{1}^{2}$ distribution with 1 df, i.e. ${\chi^{2} = F}^{- 1}\left( 1 - P' \right.$\|$~\lambda^{2} = 0$),Transform $\chi^{2}$ to a 'central' Z-score: $Z^{'} = sign\left( Z \right)*~\sqrt{\chi^{2}}$.By Delta method (a first order Taylor approximation), $Z^{'}$ as a linear transformation (deflation) of $Z$ has the same correlation structure. Thus, $Z^{'}$ can be used to build the competitive gene statistics ([Supplementary Text S1](#sup1){ref-type="supplementary-material"}), which has the same variance as their non-competitive versions.

To facilitate user-specific input along with future extensions, the new annotation file now includes a R-like formula for the expression of each gene as a function of its eQTL genotypes. The annotation file includes cis-eQTL for all tissues available in PREDICTDB (<http://predictdb.hakyimlab.org/>[).]{.ul} To avoid making inference about genes poorly predicted by SNPs, for the $44$ available tissues we retain only genes for which the expression is predicted with *q*-value $< 0.05$ from its eQTLs. Additionally, given the increased deleteriousness of rarer mutations, we offer the possibility to upweight coefficient of rarer variants ([Supplementary Text S1](#sup1){ref-type="supplementary-material"} for statistic computation) using a Madsen and Browning type approach ([@btx509-B8]). For linkage disequilibrium (LD) estimates in cosmopolitan cohorts (needed for both imputation and statistical inference), we allow user to input the study cohort proportions of ethnicities from the reference panel. LD patterns of the study cohort are estimated as a weighted mixture (with the above weights) of the LD matrices for all ethnic groups in a reference panel ([Supplementary Text S2](#sup1){ref-type="supplementary-material"}). LD patterns are subsequently used to (i) accurately impute summary statistics of unmeasured eQTLs ([Supplementary Text S3](#sup1){ref-type="supplementary-material"}) and (ii) compute the variance of the SNP linear combinations used for gene level tests in each tissue ([Supplementary Text S2](#sup1){ref-type="supplementary-material"}). The current version uses the 1000 genome (1KG) Phase I release version 3 as reference panel ([@btx509-B2]). It consists of $379~$Europeans, $286$ Asians, $246$ Africans and $181$ Native Americans.

3 Simulations
=============

To estimate the false positive rates of JEPEGMIX2, for five different cosmopolitan studies scenarios ([Supplementary Text S4](#sup1){ref-type="supplementary-material"}), we simulated (under $H_{0}$) 100 cosmopolitan cohorts of 10, 000 subjects for Ilumina 1 M autosomal SNPs using 1KG haplotype patterns ([Supplementary Text S4](#sup1){ref-type="supplementary-material"}, [Supplementary Table 1](#btx509-T1){ref-type="table"}). The subject phenotypes were simulated independent of genotypes as a random Gaussian sample. SNP phenotype-genotype association summary statistics, were computed as a correlation test. We obtained JEPEGMIX2 statistics for: (i) competitive (C), non-competitive (NC) and (ii) tests with rare (Madsen and Browning like) (R) and non-rare (NR) eQTL weights. To test the ability of methods to maintain false positive rates under background enrichment, we provide an enriched scenario. Under this scenario, we quantile transform the simulated 'central' Z-score (CZ) to a 'non-central' Z-score (NCZ) scenario by following the three steps from the previous section with the first step having noncentrality $\lambda^{2} = 0$ and the second one $\lambda^{2} = 0.5$ \[extrapolation of PGC3 Schizophrenia nocentrality from PGC2 $\lambda^{2}$ ([@btx509-B13])\]. We also applied JEPEGMIX2 to 16 real summary datasets ([Supplementary Text S5](#sup1){ref-type="supplementary-material"}, [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). To limit the increase in Type I error rates of JEPEGMIX2, we deem as significantly associated only genes with Holm-adjusted *P*-value (*q*-value)$< 0.05.$ Due to C4 explaining most of Major Histocompatibility (MHC) (chr6: 25--33 Mb) ([@btx509-B10]), signals for schizophrenia (SCZ), for this trait, we omit non-C4 genes in this region.

4 Results
=========

JEPEGMIX2 with competitive (C) statistics, controls the false positive rates at or below nominal thresholds for both central (CZ) and non-central (NCZ) scenarios while the non-competitive (NC) has similar behavior only for the central case (when the GWAS statistics are not enriched) ([Supplementary Text S5](#sup1){ref-type="supplementary-material"}, Supplementary Figs S1--S5). Under the enriched scenario (NCZ) the non-competitive version of the test has much increased false positive rates.

Using the Holm *P*-value adjustment and both rare (R) and non-rare (NR) e QTL weights, for the real datasets significant gene signals were found in 9 traits, for which we present heatmaps ([Supplementary Text S5](#sup1){ref-type="supplementary-material"}, Supplementary Figs S6--S23). The number of genes with *q*-value $<  0.05$ is presented in [Table 1](#btx509-T1){ref-type="table"} (for the abbreviations see [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Each analysis ran in less than 3 h on a cluster node with 4× Intel Xeon 6 core 2.67 GHz. Table 1.Signals for real datasetsTraitsNo unique genesSCZ$68$ALZ$34$AMD$17$BIP$11$HDL$79$LDL$78$T2D$5$TG$48$Smoking$5$

5 Conclusions
=============

We propose JEPEGMIX2, an updated software/method for testing the association between (cis-eQTL mediated) gene expression and trait. Unlike existing methods, even for highly enriched GWAS, JEPEGMIX2 competitive version fully controls the false positive rates at or below nominal levels. To the applicability of JEPEGMIX to cosmopolitan cohorts, we add a competitive version and extend the number of included (i) eQTLs and (ii) tissues. Unlike existing methods, it also accommodates up weighting of the rare variants and avoids the increased rate of false positives incurred by FDR adjustment (under enrichment) by using a Holm adjustment. While gene expression in different tissues are often correlated and incomplete due to the rather small sample sizes of existing gene expression experiments, the capacity of discriminating causal tissues will be enhanced by further increases in sample size of such studies. Being written in C ++, JEPEGMIX2 is very fast. Future versions of the software will use larger reference panels.
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